Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.

Pathology oncology research : POR - 1 Jan 2023

Moldvay Judit, Tímár József

Abstract excerpt

KRAS mutant lung cancer is the most prevalent molecular subclass of adenocarcinoma (LUAD), which is a heterogenous group depending on the mutation-type which affects not only the function of the oncogene but affects the biological behavior of the cancer as well. Furthermore, KRAS mutation affects radiation sensitivity but leads also to bevacizumab and bisphosphonate resistance as well. It was highly significant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Biology
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Piperazines

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 38239281
DOI: 10.3389/pore.2023.1611580
PMCID: PMC10794394

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.PMID 38239281Read ↗

Current perspectives of KRAS in non-small cell lung cancer.Semantic proximity Read ↗

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.Semantic proximity Read ↗

KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges.Semantic proximity Read ↗

Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential.Semantic proximity Read ↗

Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity.Semantic proximity Read ↗

KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.Semantic proximity Read ↗

Targeting KRAS G12C in non-small cell lung cancer: Breakthrough inhibitors and combination approaches.Semantic proximity Read ↗

KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies.Semantic proximity Read ↗

Current therapy of KRAS-mutant lung cancer.Semantic proximity Read ↗

Treating KRAS -mutant NSCLC: latest evidence and clinical consequencesSemantic proximity Read ↗

Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review).Semantic proximity Read ↗

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic StrategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.